跳转至内容
Merck
CN

Y0000336

甲巯咪唑

European Pharmacopoeia (EP) Reference Standard

别名:

1-甲基-2-咪唑硫醇, 2-巯基-1-甲基咪唑

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C4H6N2S
化学文摘社编号:
分子量:
114.17
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
108646
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

甲巯咪唑, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)

SMILES string

CN1C=CNC1=S

InChI key

PMRYVIKBURPHAH-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

thiamazole

manufacturer/tradename

EDQM

mp

144-147 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... TPO(7173)

正在寻找类似产品? 访问 产品对比指南

Application

Thiamazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Health hazardExclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - Skin Sens. 1

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Fernando Bolaños et al.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 54(4), 307-310 (2002-11-06)
Long-term thionamide treatment is considered one of the main resources for Graves' hyperthyroidism. Although a 54.2% remission rate in patients so treated in Mexico was previously reported, most articles have shown a wide variation over time. In the present article
Ashish A Vyas et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 16(4), 673-676 (2010-05-05)
To report a case of a patient with Graves disease presenting with agranulocytosis induced by methimazole, with subsequent thyroid storm and successful therapeutic use of plasmapheresis. The clinical features and laboratory findings in a patient with agranulocytosis and thyroid storm
M Clementi et al.
American journal of medical genetics, 83(1), 43-46 (1999-03-17)
We report on a further case of congenital anomalies in a child exposed to methimazole during the first trimester of pregnancy (from first to seventh gestational week), and define a specific malformation pattern related to prenatal methimazole exposure and consisting
P Barbero et al.
American journal of medical genetics. Part A, 129A(1), 83-86 (2004-07-22)
We report three patients with bilateral choanal atresia in children prenatally exposed to methimazole (MMI) in order to define a MMI embryopathy clinical pattern. The combination of choanal atresia and other specific malformations strongly resembles previously reported patients exposed to
T Vogt et al.
The British journal of dermatology, 133(6), 994-996 (1995-12-01)
We report a child with scalp aplasia cutis congenita, whose mother was treated with methimazole during pregnancy. The relationship between antithyroid drug administration during pregnancy and the occurrence of scalp defects is discussed, and the pertinent literature is reviewed.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持